CERO Therapeutics Holdings, Inc. has entered into a new stock purchase agreement allowing it to sell up to $20.59 million of its common stock to an investor, following a previous agreement where it sold 23.38 million shares for $4.41 million. Additionally, stockholders approved several proposals, including a potential reverse stock split and an increase in shares available under the equity incentive plan.